Saturday, 20 October 2018

Intra-tumoural injections- poster discussions

1. SD101- Tol9 receptor agonist plus PD1 in - not sure why you would do that- PD1 naive patients

data for PDL1 status needs to be verified as inconsistent

Interesting bit in here is that seems that the higher dose works less well than the lower dose

check poster

2. TLR9-agonister (Tilosotolimod) IMO-2125 plus Ipi in PD1 refractory patients, so the ones who failed PD1 treatment

response in injected and also in un-injected lesions

look into which T-cells clones expanded

3. T-Vec in IIIB-IVM1c patients 

biopsies at baseline and day1 of week 6- looking at CD8+ density

no correlate between density and objective response but durable response (objective response >6 months)

change in density didn't correlate with either


but- they change of CD8+ was seen also in uninjected lesions, so there IS a systemic effect of the T-Vec

4. Pembro plus Dab/Tram intermittendly- IMPEMBRA

small numbers, so caution

Hardly novel trial reasoning- better responses early on targeted therapy than on immune therapy- but different lengths of treatment with Dab/Tram 

but seems that the Dab/Tram combination creates a favourable environment for immune therapy READ UP

No comments:

Post a Comment

ESMO 2018 Congress TV: Protecting Patients from Fake News with Gilliosa ...

Fake News and Pseudoscience are dangerous for patients.  So very pleased and incredibly proud to see Gilly's session covered on the ...